Related Experiment Video
Updated: Jul 18, 2026
Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay
Published on: March 1, 2011
Value of blood tests including serum group IIA phospholipase A2 and bactericidal/permeability-increasing protein in
M M Haapamäki1, J Grönroos, H Nurmi
1Department of Surgical and Perioperative Sciences, Surgery, Umeå University Hospital, Umeå, Sweden. markku.haapamaki@vll.se
Insights
Blood tests show limited ability to predict Crohn's disease activity or outcomes. While serum group IIA phospholipase A2 indicates inflammation, no single test reliably predicts disease course in Crohn's patients.
Area of Science:
- Gastroenterology
- Clinical Chemistry
- Immunology
Background:
- Assessing Crohn's disease activity is challenging due to reliance on subjective symptoms and non-specific lab tests.
- Current diagnostic guidelines primarily focus on endoscopic findings.
- There is a need for objective markers to evaluate disease status and predict outcomes.
Purpose of the Study:
- To evaluate the efficacy of various blood tests in differentiating Crohn's disease patient groups.
- To determine if blood tests can predict clinical disease activity and long-term outcomes.
Main Methods:
- 73 Crohn's disease outpatients were assessed using a clinical score and 22 laboratory blood tests.
- Patients' clinical outcomes were tracked over a 6-year follow-up period.
- Logistic regression models were used to predict disease activity and outcomes.
Main Results:
- Serum group IIA phospholipase A2 and alpha-1-antitrypsin were frequently abnormal in active Crohn's disease.
- Weak correlations were observed between clinical scores and most blood tests; serum lysozyme showed the best correlation (r=0.40).
- Serum orosomucoid and lysozyme best predicted disease activity at study entry, while serum albumin best predicted long-term clinical outcome.
Conclusions:
- Serum group IIA phospholipase A2 is a sensitive marker for inflammation in Crohn's disease.
- The studied blood tests do not reliably predict disease activity or clinical outcomes in Crohn's disease patients.
Objective:
Determination of the activity of Crohn's disease at a defined time-point is a challenging task since only endoscopy guidelines are given and secondary clinical findings, subjective symptoms and non-specific laboratory tests have therefore to be relied on. The purpose of the current study was to investigate the ability of blood tests to differentiate patient groups with different clinical disease activity and different clinical outcomes during follow-up in Crohn's disease.
Material And Methods:
During a visit to hospital, 73 outpatients with Crohn's disease were examined, a clinical score was calculated and blood samples were collected for 22 laboratory tests. The patients were also grouped according to clinical outcome during a 6-year follow-up.
Results:
Serum group IIA phospholipase A2 and alpha-1-antitrypsin values were outside the reference interval more frequently (62% and 42%, respectively) than the other tests in active Crohn's disease. Only weak correlations were found between the clinical score and the test values, and the best correlation was found with serum lysozyme (r = 0.40). In a logistic regression model, the best prediction of disease activity at entry to the study was reached with a model including serum orosomucoid and serum lysozyme and the best prediction of clinical outcome during follow-up was reached using a model including serum albumin.
Conclusions:
Serum group IIA phospholipase A2 appeared to be the most sensitive marker of inflammation in Crohn's disease among the 22 blood tests compared. No reliable predictions of disease activity at the time of blood sampling or clinical outcome later during follow-up could be made from the blood tests studied.
More Related Videos
09:44Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
Published on: October 14, 2025
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
Related Concept Videos
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
01:20Inflammatory Bowel Disease IV: Clinical Manifestations
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
01:30Serum Laboratory Studies, Stool Test, Breath Test
01:25Inflammatory Bowel Disease III: Crohn's Disease